Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma.

Trial Profile

Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via eFlow Nebuliser and Conventional Budesonide Inhalation Suspension (Pulmicort Respules) Delivered via LC Plus Jet Nebuliser in Adult Patients with Mild To Moderate Persistent Asthma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Verus Pharmaceuticals

Most Recent Events

  • 28 Jul 2017 Status changed from recruiting to completed (Global end Date:22-02-2007).
  • 21 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top